Precision Radiotherapy for Lung Cancer: New Possibilities Even with Metastases

A diagnosis of “lung cancer” still sounds frightening. It’s especially hard for patients to hear that the disease has spread beyond the primary tumor and metastases have appeared.

However, in recent years the treatment of lung cancer has changed significantly. Immunotherapy, targeted drugs, molecular diagnostics, and modern radiation therapy techniques now allow doctors, in some cases, to control the disease over the long term, preserve quality of life, and continue effective treatment even when individual new lesions appear.

One such method is high-precision, or stereotactic, radiation therapy.

What happens when treatment is working, but individual metastases keep growing?

Modern treatment for advanced lung cancer often includes immunotherapy or targeted drugs. They act on tumor cells throughout the body and can hold the disease’s progression in check for an extended period.

But tumor cells are not uniform. Sometimes most lesions respond well to the drug, while one or several metastases gradually develop resistance and begin to grow.

This condition is called oligoprogression: the disease overall remains under control, but individual tumor lesions stop responding to the ongoing therapy.

In the past, such a situation often meant switching the entire treatment regimen. Today, doctors can consider a different approach: targeting the resistant metastases precisely with high-precision radiation therapy, while keeping the drug that continues to control the remaining lesions.

This is especially important if the drug is well tolerated and remains effective for most of the tumor process.

How does high-precision radiation therapy work?

Modern equipment can deliver a high dose of radiation directly to the tumor lesion with millimeter-level precision.

Careful planning is carried out before treatment begins. Doctors use computed tomography and, when needed, PET-CT, MRI, and other imaging methods. Specialized software determines the tumor’s shape, size, and exact location, and calculates a safe beam trajectory.

Radiation is delivered from multiple angles and converges on the site of the metastasis. Surrounding healthy tissue receives a significantly lower dose in the process.

This approach can be used to treat individual lesions in the lungs, brain, liver, bones, adrenal glands, and other organs — where it is technically feasible and consistent with the overall clinical picture.

Does this always require lengthy treatment?

Not necessarily. In a number of cases, stereotactic radiation therapy is performed on an outpatient basis and involves just a few sessions.

The procedure itself is painless. The patient is positioned precisely, and the medical team monitors the process from an adjacent room. Hospitalization is most often not required, although the final decision depends on the tumor’s location, the patient’s overall condition, and the chosen treatment program.

The number of sessions and the radiation dose are determined individually. There is no universal formula here: the same diagnosis in different patients may call for entirely different decisions.

Why is it important not to switch effective treatment too soon?

Each new line of drug therapy has its own characteristics, limitations, and possible side effects. In addition, the number of available treatment options is not unlimited.

If the current drug continues to control most of the tumor lesions, preserving it can be a significant advantage. Local irradiation of a resistant metastasis can sometimes delay the switch to the next regimen and extend the period of disease stability.

But this does not mean that targeted irradiation is suitable for every patient. The decision depends on several factors:

• • the number and location of progressing metastases;

• • the type of lung cancer and its molecular characteristics;

• • how the remaining lesions are responding to treatment;

• • the patient’s overall condition;

• • lung and other organ function;

• • any radiation therapy received previously;

• • proximity of the tumor to critical structures.

That is why the strategy should be discussed not by a single specialist, but by a multidisciplinary team.

Treating lung cancer is teamwork

In complex cases, a patient’s documents are reviewed by an oncology tumor board. The discussion may involve an oncologist, a radiation oncologist, a thoracic surgeon, a pulmonologist, a radiologist, a nuclear medicine specialist, and a pathologist.

The team evaluates the disease as a whole and answers the key question: which combination of methods will give this particular patient the greatest benefit with an acceptable burden on the body?

Sometimes the optimal solution is to continue drug therapy combined with local irradiation. In another situation, a change of drug, surgery, or a different approach may be needed.

That is precisely why, before changing treatment, it can be especially useful to get a second opinion at a specialized oncology center.

Technology matters, but the patient needs more than just technology

High-precision equipment alone does not replace a doctor’s experience. The indications must be determined correctly, the dose calculated, the tumor’s movement during breathing accounted for, and healthy tissue protected as much as possible.

The human side of treatment matters just as much. Patients need to understand why the procedure has been prescribed, what to expect during the course, and what reactions the body may have afterward.

Modern oncology is not only about fighting the tumor. It is also about preserving independence, everyday activity, and the highest possible quality of life.

Metastases no longer always mean running out of options

Metastatic lung cancer remains a serious disease. The same outcome cannot be promised to every patient, and high-precision radiation therapy is not a universal solution.

But today, the appearance of individual metastases does not always mean treatment options are exhausted. In certain clinical situations, resistant tumor lesions can be targeted with precision irradiation while preserving the systemic therapy that continues to work.

This allows doctors to act more precisely, and patients to receive treatment adapted not only to their diagnosis, but to the specific way their disease is developing.

How to get a second opinion in Switzerland?

An initial evaluation does not always require traveling to Switzerland right away. Medical documents can first be sent to the specialists:

• • the oncologist’s report;

• • histology and molecular-genetic test results;

• • CT, PET-CT, or MRI reports and images;

• • information about treatment already received;

• • a list of current medications;

• • the most recent test results.

After reviewing the documents, it becomes possible to determine whether a consultation with a radiation oncologist makes sense, whether high-precision radiation therapy is suitable for the patient, and whether an in-person visit is required.

Russo Unique Services arranges the review of medical documentation, obtaining a second opinion, and consultations with relevant specialists in Switzerland. If needed, we also coordinate examinations, treatment, and the patient’s stay.

Every case requires individual assessment. The more complete the medical information provided, the more precise the specialists’ preliminary conclusion can be.